GSK1160724 is a long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. The LAMA program is one of three respiratory programs under joint development by GlaxoSmithKline (GSK) and Theravance.
Michael Kitt, senior vice president of development at Theravance, said: “The goal of our program is to develop an effective once-a-day inhaled medicine that is better tolerated than the market leaders. In addition, at higher doses, a more lung-selective LAMA might offer improved efficacy with comparable or improved tolerability.”